

**IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF NEW JERSEY**

JANSSEN PHARMACEUTICALS,)
INC.)
)
Plaintiff,)
)
v.) Civil Action No. _____
)
VINTAGE PHARMACEUTICALS,)
LLC,)
)
Defendant.)

COMPLAINT FOR PATENT INFRINGEMENT

Plaintiff Janssen Pharmaceuticals, Inc., by its attorneys, for its complaint against Vintage Pharmaceuticals, LLC (“Vintage Pharmaceuticals” or “Defendant”) alleges as follows:

The Parties

1. Plaintiff is a corporation organized and existing under the laws of Pennsylvania with its principal place of business at 1125 Trenton-Harbourton Road, Titusville, New Jersey 08560.
2. Upon information and belief, Defendant Vintage Pharmaceuticals is a corporation organized under the laws of Delaware, with a principal place of business at 130 Vintage Drive, Huntsville, Alabama

35811. Upon information and belief, Vintage Pharmaceuticals also does business under the name Qualitest Pharmaceuticals.

3. Upon information and belief, Defendant manufactures generic drugs for sale and use throughout the United States, including in this judicial district, alone and/or through subsidiaries and agents. Upon further information and belief, Vintage Pharmaceuticals has directed other activities at New Jersey, including registering to do business in New Jersey and appointing a registered agent to accept service of process there.

Jurisdiction and Venue

4. This is a civil action for patent infringement arising under the patent laws of the United States, 35 U.S.C. § 271(e)(2) and 21 U.S.C. § 355.

5. This Court has jurisdiction over the subject matter of this action pursuant to 28 U.S.C. §§ 1331 and 1338(a).

6. This Court has specific personal jurisdiction over Vintage Pharmaceuticals by virtue of the fact that, as noted below, on or about April 16, 2015, Vintage Pharmaceuticals sent a Paragraph IV notice letter to Plaintiff in New Jersey, alleging that Plaintiff's United States Patent No. 6,214,815 ("the '815 Patent") is anticipated, obvious, and invalid, and informing Plaintiff that Vintage Pharmaceuticals seeks approval to engage in

the commercial manufacture, use, and sale of a product bioequivalent to ORTHO TRI-CYCLEN® LO, which is covered by the '815 Patent, prior to the expiration of the '815 Patent. By doing so, Vintage Pharmaceuticals purposefully directed its activities to New Jersey, giving rise to a tortious act of patent infringement that results from, and relates to, Vintage Pharmaceuticals' contact with Plaintiff in New Jersey.

7. In addition, upon information and belief, Vintage Pharmaceuticals has consented to jurisdiction in this District by registering to do business and appointing a registered agent to accept service of process in New Jersey, and by conducting substantial sales in New Jersey.

8. Venue is proper in this judicial district pursuant to 28 U.S.C. §§ 1391 and 1400(b).

Count 1: Patent Infringement

9. Plaintiff incorporates by reference the allegations contained in paragraphs 1 to 8 above.

10. The '815 Patent, entitled "TRIPHASIC ORAL CONTRACEPTIVE," was duly and legally issued by the United States Patent and Trademark Office ("USPTO") on April 10, 2001. Plaintiff is the owner of the '815 Patent. A copy of the '815 Patent is attached hereto as Exhibit A.

11. Plaintiff currently markets a prescription oral contraceptive product under the trademark ORTHO TRI-CYCLEN® LO. ORTHO TRI-CYCLEN® LO is covered by the claims of the '815 Patent.

12. Plaintiff is the holder of an approved New Drug Application ("NDA") covering ORTHO TRI-CYCLEN® LO.

13. Upon information and belief, Vintage Pharmaceuticals submitted Abbreviated New Drug Application ("ANDA") No. 207608 to the FDA seeking approval to engage in the commercial manufacture, use, offer for sale, and sale of a generic version of ORTHO TRI-CYCLEN® LO before the expiration of the '815 Patent. Defendant's manufacture, use, offer for sale, or sale of such product would infringe the claims of the '815 patent under 35 U.S.C. § 271(a), (b), and/or (c).

14. As part of its ANDA filing, Vintage Pharmaceuticals has purportedly provided written certification to the FDA that the claims of the '815 Patent are invalid and/or will not be infringed by the manufacture, use, or sale of Vintage Pharmaceuticals' generic version of ORTHO TRI-CYCLEN® LO.

15. By letter dated April 16, 2015, Vintage Pharmaceuticals gave written notice of its certification of invalidity and/or noninfringement of the '815 Patent, alleging that the '815 Patent is anticipated, obvious, and

invalid, and informing Plaintiff that Vintage Pharmaceuticals seeks approval to engage in the commercial manufacture, use, and sale of a product bioequivalent to ORTHO TRI-CYCLEN® LO prior to the expiration of the '815 Patent.

16. Vintage Pharmaceuticals has infringed the '815 Patent under 35 U.S.C. § 271(e)(2)(A) by virtue of submitting ANDA No. 207608 with a Paragraph IV certification and seeking FDA approval of ANDA No. 207608 prior to the expiration of the '815 Patent. Moreover, if Vintage Pharmaceuticals commercially uses, offers for sale or sells its generic version of ORTHO TRI-CYCLEN® LO, or induces or contributes to such conduct, it would further infringe the '815 patent under § 271(a), (b), and/or (c).

17. This case is an exceptional one, and Plaintiff is entitled to an award of its reasonable attorney fees under 35 U.S.C. § 285.

18. Plaintiff will be irreparably harmed if Defendant is not enjoined from infringing or actively inducing or contributing to infringement of the '815 Patent. Plaintiff does not have an adequate remedy at law.

Prayer for Relief

WHEREFORE, Plaintiff seeks the following relief:

A. A judgment that Defendant has infringed the '815 Patent under 35 U.S.C. § 271(e)(2)(A);

B. An order pursuant to 35 U.S.C. § 271(e)(4)(A) providing that the effective date of any FDA approval of ANDA No. 207608 is not earlier than the expiration date of the '815 Patent, or any later expiration of exclusivity for the '815 Patent to which Plaintiff is or becomes entitled;

C. A permanent injunction restraining and enjoining Defendant and its officers, agents, servants, and employees, and those persons in active concert or participation with any of them, from making, using, selling, offering to sell, or importing the product described in ANDA No. 207608;

D. A judgment declaring that the making, using, selling, offering to sell, or importing of the product described in ANDA No. 207608 would constitute infringement of the '815 Patent, or inducing or contributing to such conduct, by Defendant pursuant to 35 U.S.C. § 271(a), (b), and/or (c);

E. A finding that this is an exceptional case, and an award of attorneys' fees in this action pursuant to 35 U.S.C. § 285;

F. Costs and expenses in this action; and

G. Such further and other relief as this Court determines to

be just and proper.

MCCARTER & ENGLISH, LLP

By: /s/ Nicholas M. Insua
Nicholas M. Insua
Cynthia S. Betz

Four Gateway Center
100 Mulberry Street
Newark, New Jersey 07102
T (973) 622 4444
F (973) 624 7070
Attorneys for Plaintiff

Of Counsel:

George F. Pappas
Jeffrey B. Elikan
Benjamin C. Block
Eric R. Sonnenschein
COVINGTON & BURLING LLP
One CityCenter,
850 Tenth Street, NW
Washington, D.C. 20001
T (202) 662-6000

May 26, 2015

CERTIFICATION PURSUANT TO L. CIV. R. 11.2

Pursuant to Local Civil Rule 11.2, I certify that this action alleges infringement of the same patent at issue in the consolidated matters *Ortho-McNeil-Janssen Pharmaceuticals, Inc., et al. v. Watson Laboratories, Ortho-McNeil-Janssen Pharmaceuticals, Inc. v. Sandoz Inc.*, and *Ortho-McNeil-Janssen Pharmaceuticals, Inc. v. Lupin Ltd., et al.*, Docket No. 08-5103 (SRC) (MAS), in the matter *Ortho-McNeil-Janssen Pharmaceuticals, Inc., et al. v. Mylan Inc., et al.*, Docket No. 10-6018 (SRC) (MAS), in the matter of *Janssen Pharmaceuticals, Inc. v. Sun Pharma Global Fze, et al.*, Docket No. 11-6089 (SRC) (CLW), in the matter of *Janssen Pharmaceuticals, Inc. v. Haupt Pharma, Inc., et al.*, Docket No. 12-3034 (SRC) (CLW), in the matter of *Janssen Pharmaceuticals, Inc. v. Glenmark Generics, Ltd., et al.*, Docket No. 12-5009 (SRC) (CLW), and of the patent at issue in *Ortho-McNeil Pharmaceutical, Inc., et al. v. Barr Laboratories, Inc.*, Docket No. 03-4678 (SRC).

/s/ Nicholas M. Insua
Nicholas M. Insua
MCCARTER & ENGLISH, LLP